In two immunologically cold melanoma tumor models, we were able to demonstrate that GPR182 ablation alone recruited sufficient effector T cells to slow tumor progression, and at the same time sensitized otherwise resistant tumors to subsequent immunotherapy. This evidence concerns the gene ACKR5 and neoplasm.